Cathie Wood Adds to WeRide (WRD) and CRISPR, Trims Ibotta (IBTA) in Holiday Trades, 12/24/25

Cathie Wood's ARK Invest ETFs (exchange-traded funds) made another round of trades on Christmas Eve, December 24, sticking with many of the same names as a day earlier. The firm continued to add to positions in WeRide (WRD) and CRISPR Therapeutics (CRSP), while trimming its stake in mobile-technology company Ibotta (IBTA).Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The largest trade once again was in WeRide Inc. (WRD), a company that develops self-driving technology. ARK bought 101,637 shares through the ARK Autonomous Technology & Robotics ETF (ARKQ) totaling $901,520. Wood continued to buy WeRide after the stock slipped 0.45% in the prior session. The purchase followed large buys earlier in the week, including 356,263 shares on December 23 and 520,697 shares on December 22, pointing to rising confidence in the company's longer-term story. ARK also added to CRISPR Therapeutics (CRSP), buying 10,353 shares through the ARK Innovation ETF (ARKK) and the ARK Genomic Revolution ETF (ARKG), for a combined value of roughly $584,530. The buy adds to earlier purchases of 43,333 shares on December 23 and 78,793 shares on December 22, showing continued interest in the gene-editing space. On the selling side, ARK made another small cut to Ibotta Inc. (IBTA). The firm sold 101 shares through its ARK Next Generation Internet ETF (ARKW), worth about $2,173. While the amount was small, it followed a similar sale of 296 shares on December 23, extending a gradual trimming pattern. Wall Street's Take on WRD, CRSP, and IBTA Let's see how these stocks perform using the TipRanks Stock Comparison Tool: Wall Street analysts have a "Strong Buy" rating on WeRide, with price targets pointing to about 67% upside over the next 12 months. Meanwhile, they remain cautiously optimistic about CRISPR, which carries a "Moderate Buy" rating, while Ibotta remains rated "Hold."